COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA

被引：0

作者：

Yu, Y. ^{[1
]}

Luan, L. ^{[2
]}

Zhu, F. ^{[3
]}

Dong, P. ^{[2
]}

Li, L. ^{[2
]}

Lin, Y. ^{[4
]}

Lu, S. ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China

[2] Pfizer Investment Co Ltd, Beijing 11, Peoples R China

[3] Pfizer Investment Co Ltd, Shanghai, Peoples R China

[4] Shanghai Palan DataRx Co Ltd, Shanghai, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN164

引用

页码：S467 / S468

页数：2